Valuation : Polaryx Therapeutics, Inc.

Market Cap 99.19M 85.31M 80.49M 73.32M 137M 9.48B 138M 959M 369M 4.81B 372M 364M 15.28B P/E 2026 *
-10.2x
P/E 2027 * -6.92x
Enterprise Value 99.19M 85.31M 80.49M 73.32M 137M 9.48B 138M 959M 369M 4.81B 372M 364M 15.28B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day+3.77%
1 week+3.50%
Current month+2.99%
1 month-5.91%
3 months-13.03%
6 months-64.06%
1 week 1.97
Extreme 1.97
2.12
1 month 1.85
Extreme 1.85
2.68
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 01/03/2023
Director of Finance/CFO 60 01/06/2024
Chief Tech/Sci/R&D Officer 56 01/09/2026
Director TitleAgeSince
Chairman 56 01/06/2021
Director/Board Member 60 01/08/2025
Director/Board Member - 29/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Buy

Chief Executive Officer

88,453 0.1868%
18/02/26 Buy

Chief Financial Officer

2,867 -
29/01/26 Other

Chief Financial Officer

225,358 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.77%+3.50% - - 99.19M
-0.67%-6.17%-4.69%+9.24% 46.05B
-0.28%-3.35%+338.99%+517.55% 43.59B
-0.03%-3.67%+35.27%+19.80% 42.35B
+1.24%-3.39%+3.11%+65.41% 38.86B
-1.26%-3.37%+11.87%+40.55% 32.24B
-0.49%-3.24% - - 17.16B
+0.81%+0.06%+18.90%+111.79% 16.28B
+0.59%-1.90%+11.47%+31.67% 14.32B
+1.19%-4.07%+73.26%+38.62% 13.03B
Average +0.49%-4.23%+61.02%+104.33% 26.4B
Weighted average by Cap. -0.02%-5.04%+72.89%+123.41%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -7.88M -7.44M -6.77M -12.66M -876M -12.78M -88.56M -34.08M -444M -34.41M -33.66M -1.41B -16.42M -14.13M -13.33M -12.14M -22.7M -1.57B -22.9M -159M -61.09M -797M -61.68M -60.33M -2.53B
Net Debt - -
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
11/09/26 $2.070 +4.02% 3,731
10/09/26 $1.990 -4.33% 17,432
09/09/26 $2.080 +2.97% 23,533
08/09/26 $2.020 +1.00% 14,363
04/09/26 $2.000 +0.50% 39,726
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.990USD
Average target price
7.500USD
Spread / Average Target
+276.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PLYX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!